As the fields of healthcare and biotechnology rapidly advance, ethical issues have increased just as quickly. Taking a look ahead, let me predicts four biggest bioethical/ethical issues of the next five years in Europe or our world today:
1. Providing a minimal level of healthcare and reducing health disparities globally.
The average global life expectancy has increased by 20 years within
the past five decades, but underdeveloped countries have been left
behind, and there is a lack of a moral framework for dealing with this
issue. Global and national actors are morally responsible for achieving
common goals that will address this global health disparity. It
stretches beyond a health issue; it is also a global peace issue, a
global security issue, and an economic issue. For example, if epidemics
are raging out of control in parts of Africa, that could lead to
international political instability, economic instability, and so on.
2. Addressing the ethical, legal, and social questions posed by new gene editing technologies.
One of the greatest genetic technologies discovered is the CRISPR-Cas
9, a tool that can alter the DNA in our cells. The procedure involves
clipping out bad genes in cells or inserting better ones. But there are
risks. Specific genes that may increase the likelihood of one disease
can protect you against other illnesses, meaning removal of such genes
does not eliminate all changes of getting a disease. Moreover, gene
editing could also lead to mistakes, such as snipping parts of the wrong
gene and risking further health damages.
3. Addressing rising ethical, legal, and social challenges posed by AI and big data.
Complex AI systems and big data analysis are becoming the norm for
corporations. Employees should understand the potential ethical risk of
algorithms and network monitoring, the use of a system to monitor a
network for slow or failing components. During this process, any data
that is digested is usually hidden from view, which places data
transparency and privacy into question.
4. Reducing the extreme costs of certain pharmaceutical products.
Many pharmaceutical companies have been raising the price of their drugs. Drug companies may expect reasonable return on their investment in
research and development, the development of new drugs depends on
taxpayer money and sacrifices that patients in studies make in good
faith. In addition, excessive price increases can harm people,
threatening public health and depleting taxpayer money that could be
better used in other ways.